VIVES is a multi-sector fund that invests in projects with a positive societal impact
About Eligo Bioscience
Eligo Bioscience is the world leader in microbiome in-vivo gene editing and is advancing a highly differentiated pipeline of precision medicines to address unmet medical needs...
GreenWatt, founded in Belgium in 2004 as a spin-off from the Catholic University of Louvain (UCLouvain), designs, develops and markets locally integrated "key-to-door" biogas plants for the food and...
Keemotion has developed a motion detection technology. Their proprietary software offers a complete solution for coaches, leagues and broadcasters. Thanks to Keemotion, your organization produces...
Gael Rouvroy, CEO intoPIX :
"VIVES fund has been a great partner in early and mature stages of intoPIX. They recognized the potential of the market and the technology with a primary recognition for...
Pierre Blondeau, CEO Upstreem :
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Willem de Vos, Professor at University of Wageningen ; Patrice Cani, Professor at UCLouvain ; Jean-Christophe Malrieu, CEO A-Mansia :
"As founders and CEO of A-mansia Biotech we experienced essential...
BiocSol succeeds in its ambition to raise a total of €10M since inception to fast-track the development of its sustainable crop protection solutions - testament to the sector’s growing interest in its
Eligo welcomes genetic medicines leader Bobby Gaspar as chair of its board of directors
Oct 1, 2024
Dr. Gaspar brings invaluable expertise to gene-editing pioneering company Eligo as it prepares
Generare raises €5m to scale the discovery of new medicines and molecules hiding in microbes